Dr. Reddy's Laboratories acquires UCB portfolio

HYDERABAD, India — Dr. Reddy’s Laboratories on Wednesday announced that it has entered into a definitive agreement to acquire a select portfolio of the established products business of UCB, in the territories of India, Nepal, Sri Lanka and Maldives. 

 

“The acquired UCB portfolio shall accelerate Dr. Reddy’s presence in the high growth areas of dermatology, respiratory and pediatrics with market leading brands like Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M, etc.,” said Alok Sonig, SVP and India business head for Dr. Reddy's. 

 

“UCB is in a strong position with a solid platform for continuous growth thanks to our core products and our promising pipeline," said Mark McDade, UCB COO. "This position allows us to enhance our focus on our key neurology portfolio in India, providing innovative solutions to patients living with severe diseases.” 

 

The transaction is expected to be closed in the first quarter of the financial year 2015-16.